Loratadine is metabolized to desloratadine. Both of them have been used for allergy treatment in children. Anatomical, physiological, and biological parameters of children and clearance of drugs vary with age. We aimed to develop a whole-body physiologically based pharmacokinetic (PBPK) model to simultaneously predict the pharmacokinetics of loratadine and desloratadine in children. Following validation using 11 adult data sets, the developed PBPK model was extrapolated to children. Plasma concentrations following oral loratadine or desloratadine to children of different ages were simulated and compared with six children data sets. After scaling anatomy/physiology, protein binding, and clearance, pharmacokinetics of the two drugs in pediatric populations were satisfactorily predicted. Most of the observed concentrations fell within the 5th-95th percentile range of the simulations in 1000 virtual children. The predicted area under the concentration-time curve (AUC) and C fell within 0.5-2.0-fold range of the observations. Oral doses of loratadine or desloratadine for children of different ages were simulated based on similar AUCs following 10 mg of loratadine or 5 mg of desloratadine for adults. Pediatric PBPK model was successfully developed to simultaneously predict plasma concentrations of loratadine and desloratadine in children of all ages. The developed pediatric PBPK model may also be applied to optimize pediatric dosage.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.6120DOI Listing

Publication Analysis

Top Keywords

loratadine desloratadine
24
desloratadine children
20
pbpk model
16
children ages
12
children
10
pharmacokinetics loratadine
8
whole-body physiologically
8
physiologically based
8
based pharmacokinetic
8
simultaneously predict
8

Similar Publications

Data mining in FAERS: association of newer-generation H1-antihistamines with nervous system disorders.

BMC Pharmacol Toxicol

December 2024

Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.

Background: H1-antihistamines are widely used to treat symptoms depending on histamine release in a variety of conditions. However, neurological adverse events have been reported in post-marketing surveillance studies and there are limited literatures comparing the neurological disorders associated with newer-generation H1-antihistamines from real-world datasets.

Aims: We performed a comparative analysis of nervous system disorders and several newer-generation H1-antihistamines including: cetirizine, loratadine, levocetirizine, desloratadine and fexofenadine.

View Article and Find Full Text PDF
Article Synopsis
  • Allergic rhinitis is a common issue in children, and while several medications like nasal corticosteroids and antihistamines are used to treat it, there's ongoing debate about the best dosage and combinations for maximum effectiveness.* -
  • A study involving 64 children compared the effects of different drug combinations alongside mometasone furoate nasal spray, measuring symptoms like nasal congestion and sneezing.* -
  • Results showed that using desloratadine twice daily or a combination of desloratadine and montelukast significantly improved symptom control compared to other treatment options.*
View Article and Find Full Text PDF
Article Synopsis
  • * Patients were split into two groups: one received both antiplatelet therapy (cilostazol and dipyridamole) and antihistamine, while the other group only received antihistamine for four weeks.
  • * Results showed that the antiplatelet group had a significantly greater reduction in Urticaria Activity Scores, improved quality of life, and decreased D-dimer levels, suggesting the combination treatment is more effective for certain CSU patients.
View Article and Find Full Text PDF

Loratadine is metabolized to desloratadine. Both of them have been used for allergy treatment in children. Anatomical, physiological, and biological parameters of children and clearance of drugs vary with age.

View Article and Find Full Text PDF

Through the utilization of fluorescence spectroscopy, electrochemical, and molecular docking methods, this research investigates the interaction between the antihistamine drug desloratadine and calf thymus double-stranded DNA (ct-dsDNA). Deoxyguanosine (dGuo) and deoxyadenosine (dAdo) oxidation signals were diminished by incubation with varying concentrations of desloratadine, as determined by differential pulse voltammetry (DPV). This change was ascribed to desloratadine's binding mechanism to ct-dsDNA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!